Treating metastatic breast cancer (MBC) in women of 70 years old or more is a frequent problem however few data are available describing the safety and efficacy of chemotherapy in elderly patients. Eribulin is validated for MBC from the 2nd line treatment onwards since two phase III studies. We present here a focus on safety and efficacy of eribulin in patients ≥ 70 years old compared to the results of younger patients in a real life cohort.
From Oct 2014 to Feb 2017, a multicentric retro-prospective study (REPROLINE) was conducted. Data concerning patient, tumor characteristics, previous treatments administered, tolerance, efficacy and outcome of eribulin were retrieved for patients treated in real life for MBC in 12 different French hospitals between Dec 2013 and Jan 2016. Data from 446 MBC patients were collected. This database was splitted in two cohorts: comparing the results from the cohort of 363 patients < 70 years old (group A) to the cohort of 83 patients ≥70 years old or more (group B).
Median age for each cohort was 56.3 and 75.4 years old. Both cohorts had similar tumour characteristics, number of metastatic sites and the median number of prior chemotherapy lines was 2. Albumine serum levels were lower in the group B with 21% of patients with albumine < 30g/L versus 13% in group A, without any statistical difference. Outcomes were similar in group A and B with respectively: median PFS of 3.67 months versus 3.7 months; HR 0.972(CI 95% 0.762-1.241), p = 0.821. median OS 10.7 months vs 10.7 months; HR 0.997 (CI95% 0.752-1.323), p = 0.984. Patients in both groups received a median number of 4 cycles. The most frequent grade 3 adverse events were neutropenia (22.9% in group A and 15.7% in group B), fatigue (6.5% group A and 13.3% group B) and neurotoxicity (4.4% and 3.6%, respectively). No statistical difference between elderly and younger patients was demonstrated. 9.6% of the total patients stopped the treatment due to fatigue.
We present here the first study focusing retro-prospectively on the tolerance and efficacy of eribulin in elderly patients in real life. In this study, eribulin in patients ≥70 years old is as effective and safe as in younger patients.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.